Share on StockTwits

OHR Pharmaceutical (NASDAQ:OHRP) Director June Sherie Almenoff purchased 3,200 shares of the stock in a transaction that occurred on Thursday, June 26th. The stock was purchased at an average cost of $8.34 per share, with a total value of $26,688.00. Following the purchase, the director now directly owns 125,366 shares in the company, valued at approximately $1,045,552. The purchase was disclosed in a filing with the SEC, which can be accessed through this link.

Separately, analysts at Brean Capital raised their price target on shares of OHR Pharmaceutical from $21.00 to $34.00 in a research note on Tuesday, June 24th. They now have a “buy” rating on the stock.

Shares of OHR Pharmaceutical (NASDAQ:OHRP) opened at 9.08 on Wednesday. OHR Pharmaceutical has a 52 week low of $5.65 and a 52 week high of $20.00. The stock’s 50-day moving average is $8.81 and its 200-day moving average is $10.97. The company’s market cap is $214.4 million.

Ohr Pharmaceutical Inc (NASDAQ:OHRP) is a biotechnology rollup company.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.